Institut Pasteur

Centre National De La Recherche Scientifique

Other

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique-cnrs

Richard Lo-Man

Claude Leclerc

Sylvie Bay

Daniele Cantacuzene

Christine Sedlik

Sophie Vicher-Guerre

Paloma Rueda

Ignacio Casal

Teresa Freire

Javier Sarraseca

The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)(I) wherein M, T, B and n ore as defined in claim

Method for preparing multiple antigen glycopeptide carbohydrate conjugates

The present invention relates to mucin glycoconjugates, and to a process of producing mucin glycoconjugates. It relates to the biological, pharmaceutical and medical applications thereof. The invention notably provides mucin glycoconjugates which do not require a protein carrier, such as KHL, to induce an immune response (anti-Tn IgG).

Enzymatic large-scale synthesis of mucin glyconjugates, and immunogenic applications thereof

The invention of the present application relates to a method for obtaining antibodies directed against a carbohydrate moiety contained in a carbohydrate peptide conjugate, by administering to a subject a composition containing a carbohydrate peptide conjugate and collecting the antibodies directed against the said carbohydrate moiety from a serum previously obtained from the subject.

Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof

Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof

Attempts to generate modified viral pseudo-particles that are capable of stably incorporating heterologous antigenic determinants has encountered a number of difficulties including inhibition of pseudo-particle formation following epitope insertion and failure of the epitope to retain its native configuration. The present invention is directed toward recombinant viral pseudo-particles of the family Parvoviridae that stably encode heterologous epitopes. Hybrid virus-like particles (VLP) were prepared by self-assembly of a modified porcine parvovirus (PPV) VP2 capsid protein carrying a CD8 or CD4 T cell epitope in the amino terminus. Immunization of mice with hybrid pseudo-particles carrying a lymphocytic choriomeningitis virus (LCMV) nucleoprotein CTL epitope, without adjuvant, induced strong cytotoxic T lymphocyte (CTL) responses against both peptide-coated- or virus-infected-target cells. Immunization of mice with hybrid pseudo-particles carrying a hepatitis B virus (HBV) T helper cell epitope, without adjuvant, induced strong T helper lymphocyte responses against the reporter epitope. These recombinant viral pseudo-particles are easily produced by the baculovirus expression system and, therefore, represent a promising and safe strategy to induce strong CTL and T-helper cell responses for the elimination of virus-infected cells.

Recombinant VP2 parvoviral pseudo-particles encoding CTL or T-helper cell epitopes

Growing community of inventors

Paris, France

Richard Lo-Man